Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

98.66
+2.832.95%
Post-market: 99.080.4200+0.43%16:21 EDT
Volume:707.70K
Turnover:69.91M
Market Cap:24.78B
PE:-12.69
High:99.58
Open:97.50
Low:97.13
Close:95.83
52wk High:124.00
52wk Low:79.52
Shares:251.20M
Float Shares:109.00M
Volume Ratio:0.85
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.7726
EPS(LYR):-5.5184
ROE:-9.30%
ROA:-5.41%
PB:1.22
PE(LYR):-17.88

Loading ...

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

MT Newswires Live
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

GlobeNewswire
·
Jun 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and BioNTech SE (BNTX)

TIPRANKS
·
Jun 01

Shionogi Wins FDA Nod for First Oral COVID-19 Post-Exposure Preventive Drug

TIPRANKS
·
Jun 01

BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-2a trial

TIPRANKS
·
Jun 01

Lamb Weston, FedEx, BioNTech, Zscaler, Larimar Trending With Analysts

TIPRANKS
·
May 30

Pfizer - With Authorization, Pfizer-BioNTech Covid-19 Vaccine Will Be Administered as a 10-ΜG Dose for All Children Aged 6 Months Through 11 Years

THOMSON REUTERS
·
May 29

BioNTech Board Expansion Signals Focus On Oncology Execution And Valuation Gap

Simply Wall St.
·
May 29

Astellas Pharma Cuts Director Slate After Outside Director Resigns

TIPRANKS
·
May 29

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live
·
May 28

Pfizer, BioNTech Prepared to Supply 2026-2027 Covid Vaccine Formula per FDA Recommendation and Upon Approval: Briefing Docs

THOMSON REUTERS
·
May 28

BioNTech Raised to Buy From Neutral by UBS

Dow Jones
·
May 28

BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says

MT Newswires Live
·
May 28

This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative. -- Barrons.com

Dow Jones
·
May 27

UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117

MT Newswires Live
·
May 27

BioNTech upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 27

GeoVax Labs discontinues development of COVID-19 vaccine candidate

TIPRANKS
·
May 27

Roth Capital ‘strongly’ agrees with GeoVax ending COVID-19 development

TIPRANKS
·
May 27

Wells Fargo Keeps Their Buy Rating on BioNTech SE (BNTX)

TIPRANKS
·
May 25